Design and synthesis of 6,7-methylenedioxy-4-substituted phenylquinolin-2(1H)-one derivatives as novel anticancer agents that induce apoptosis with cell cycle arrest at G2/M phase

Article abstract of DOI:10.1016/j.bmc.2013.06.046

Novel 6,7-methylenedioxy-4-substituted phenylquinolin-2(1H)-one derivatives 12a-n were designed and prepared through an intramolecular cyclization reaction and evaluated for in vitro anticancer activity. Among the synthesized compounds, 6,7-methylenedioxy-4-(2,4-dimethoxyphenyl)quinolin-2(1H)-one (12e) displayed potent cytotoxicity against several different tumor cell lines at a sub-micromolar level. Furthermore, results of fluorescence-activated cell sorting (FACS) analysis suggested that 12e induced cell cycle arrest in the G2/M phase accompanied by apoptosis in HL-60 and H460 cells. This action was confirmed by Hoechst staining and caspase-3 activation. Due to their easy synthesis and remarkable biological activities, 4-phenylquinolin-2(1H)-one analogs (4-PQs) are promising new anticancer leads based on the quinoline scaffold. Accordingly, compound 12e was identified as a new lead compound that merits further optimization and development as an anticancer candidate.

Full text of DOI:10.1016/j.bmc.2013.06.046

Accepted Manuscript
Design and synthesis of 6,7-methylenedioxy-4-substituted phenylquino‐
lin-2(1H)-one derivatives as novel anticancer agents that induce apoptosis with
cell cycle arrest at G2/M phase
Yi-Fong Chen, Yi-Chien Lin, Po-Kai Huang, Hsu-Chin Chan, Sheng-Chu Kuo,
Kuo-Hsiung Lee, Li-Jiau Huang
PII:
S0968-0896(13)00577-4
DOI:
http://dx.doi.org/10.1016/j.bmc.2013.06.046
BMC 10939
Reference:
To appear in:
Bioorganic & Medicinal Chemistry
Received Date:
Revised Date:
Accepted Date:
9 May 2013
12 June 2013
19 June 2013
Please cite this article as: Chen, Y-F., Lin, Y-C., Huang, P-K., Chan, H-C., Kuo, S-C., Lee, K-H., Huang, L-J.,
Design and synthesis of 6,7-methylenedioxy-4-substituted phenylquinolin-2(1H)-one derivatives as novel
anticancer agents that induce apoptosis with cell cycle arrest at G2/M phase, Bioorganic & Medicinal Chemistry
(2013), doi: http://dx.doi.org/10.1016/j.bmc.2013.06.046
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting proof before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Design and synthesis of 6,7-methylenedioxy-4-substituted
phenylquinolin-2(1H)-one derivatives as novel anticancer agents that induce
apoptosis with cell cycle arrest at G2/M phase
Yi-Fong Chena, Yi-Chien Linb, Po-Kai Huangb, Hsu-Chin Chanc, Sheng-Chu Kuob,
Kuo-Hsiung Leed,e*, Li-Jiau Huanga,b*
aThe Ph.D. Program for Cancer Biology and Drug Discovery, China Medical
University, No.91 Hsueh-Shih Road, Taichung, Taiwan 40402, R.O.C.
bGraduate Institute of Pharmaceutical Chemistry, China Medical University, No.91
Hsueh-Shih Road, Taichung, Taiwan 40402, R.O.C.
cDepartment of Biochemistry, School of Medicine, China Medical University, No.91
Hsueh-Shih Road, Taichung, Taiwan 40402, R.O.C.
dNatural Products Research Laboratories, UNC Eshelman School of Pharmacy,
University of North Carolina, Chapel Hill, North Carolina 27599-7568, USA
eChinese Medicine Research and Development Center, China Medical University
Hospital, Taichung, Taiwan 40402, R.O.C.
*Corresponding authors. KHL: Tel.: (919) 962-0066; fax: (919) 966-3893; e-mail:
khlee@unc.edu; LJH: Tel.: +886 4 22053366 / Ext 1007; fax: +886 4 22030760;
e-mail: ljhuang@mail.cmu.edu.tw.
1

Abstract
Novel 6,7-methylenedioxy-4-substituted phenylquinolin-2-one derivatives 12a-n were
designed and prepared through an intramolecular cyclization reaction and evaluated
for in vitro anticancer activity. Among the synthesized compounds,
6,7-methylenedioxy-4-(2,4-dimethoxyphenyl)quinolin-2(1H)-one (12e) displayed
potent cytotoxicity against several different tumor cell lines at a sub-micromolar level.
Furthermore, results of fluorescence-activated cell sorting (FACS) analysis suggested
that 12e induced cell cycle arrest in the G2/M phase accompanied by apoptosis in
HL-60 and H460 cells. This action was confirmed by Hoechst staining and caspase-3
activation. Due to their easy synthesis and remarkable biological activities,
4-phenylquinolin-2(1H)-one analogs (4-PQs) are promising new anticancer leads
based on the quinoline scaffold. Accordingly, compound 12e was identified as a new
lead compound that merits further optimization and development as an anticancer
candidate.
Keywords
4-Phenylquinolin-2(1H)-one (4-PQ), Anticancer agent, Podophyllotoxin, Apoptosis,
Structure-activity relationships (SAR).
2

1. Introduction
Cancer is the leading cause of death in economically developed countries and the
second leading cause of death in developing countries.1 Development of novel
antitumor agents with cytotoxicity against cancer cell lines is an important focus of
oncology. Natural products are often referred to as an inexhaustible source of lead
compounds that are likely to exhibit multiple biological activities, including
anticancer.2,3 Because of their intrinsic biorelevance, natural products represent a
significant source of inspiration for the design of structural analogues with new
pharmaceutical profiles.
The microtubule network is an essential component of the cytoskeleton of
eukaryotic cells. Podophyllotoxin (PPT, 1) is a aryltetralin lignan isolated from the
roots of Podophyllum peltatum L., P. emodi W., or P. pleianthum H..4 PPT inhibits
tubulin assembly and polymerization through interaction with the protein at the
colchicine binding site, thus preventing the formation of the spindle, and arresting cell
division in metaphase (G2/M stage).5-7 Numerous efforts have been made to improve
PPT’s safety profile while maintaining its potency. Thus, its use as a lead agent in the
development of new anticancer drugs has led to the discovery of semisynthetic
derivatives, such as etoposide (2) and teniposide (3), and a more soluble prodrug of
etoposide, named etopophos (4) (Fig. 1). Semisynthetic derivatives of PPT are
currently in clinical use for the treatment of various malignancies.
[Figure 1 should be inserted here]
PPT’s structure is complex due to the presence of four chiral carbons in ring C
(Fig. 1), which creates challenges for SAR (structure–activity relationship) studies.
3

Research efforts to develop new analogues with simpler structures are ongoing ot
identify the critical substructures for desired biological activity, and almost all rings
(ring A to E) and positions on the cyclolignan skeleton have been modified.8
Importantly, elimination of the stereogenic centers at C-2 and C-3 removes the
possibility of epimerization at C-2. Epimerization of the natural lignan has plagued its
clinical development, because the rapidly formed in vivo cis-lactone metabolite is
inactive.9 Numerous attempts have been made to obtain potent synthetically feasible
analogues of PPT with a heteroatom incorporated in ring C to prevent epimerization.
4-Aza-podophyllotoxin (5) (Fig. 2) and related analogues were identified as
structurally simpler derivatives of PPT with reported antiproliferative activity.10-12 In
addition, podophyllic aldehyde (6) was found to be a highly selective antitumor agent
against HT-29 colon and A-549 lung carcinomas. Several aldehydes related to this
compound but with different configurations have been synthesized and evaluated for
cytotoxic activities in neoplastic cell lines.13,14 These podophyllic aldehyde-related
compounds lacked the lactone ring, but maintained cytotoxicity at, or under,
micromolar level.
[Figure 2 should be inserted here]
Another naturally occurring cis-stilbene, combretastatin A-4 (CA-4, 7) (Fig. 2)
was isolated from the bark of the south African tree Combretum caffrum
(Combretaceae).15 CA-4 is a potent tubulin assembly inhibitor and vascular disrupting
agent at low concentrations.16 Its relative molecular simplicity suggests numerous
practical approaches to the design of new antineoplastic agents, and several active
stilbene-based compounds have been identified.17 The main disadvantage of CA-4 is
the ready isomerization of its cis-double bond to an inactive trans-form during storage
4

and administration.18 Consequently, this double bond in the cis-stilbene motif has
often been used as a modification site and replaced with various heterocyclic or
carbonyl functional groups.19-21
According to previous SAR studies on PPT and related analogues, structurally
modified compounds that lack the trans-γ-lactone ring (ring D) can show potent and
selective cytotoxicity against cancer cells. Thus, the γ-lactone ring is not an essential
feature for cytotoxicity of PPT analogues. These results encouraged us to select
4-aza-podophyllotoxin (5) as the template and design much simpler structures without
a γ-lactone ring. In our previous investigation, 2-phenylquinolin-4(1H)-one analogs
(2-PQs) (Fig. 2) were identified as antimitotic agents.22 Recently, we shifted the
phenyl ring on the quinolinone from the C-2 to C-4 position. Hence, a series of
4-phenylquinolin-2(1H)-one analogs (4-PQs) was designed that mimics the structures
of 5–7 (Fig. 3). In addition, the two aromatic rings (B and E) of
4-phenylquinolin-2(1H)-one derivatives (4-PQs) adopt a conformation in which they
are not coplanar, and the structural similarity between CA-4 and appropriately
substituted 4-PQs might lead to interaction at the colchicine site to affect tubulin
polymerization. Moreover, 4-PQ compounds would not be inactivated by cis to trans
isomerization as with CA-4 derivatives.
[Figure 3 should be inserted here]
In this article, we describe the synthesis and cytotoxicity evaluation of
6,7-methylenedioxy-4-substituted phenylquinolin-2(1H)-one derivatives 12a-n (Fig.
3). Also, additional biological studies have been performed to analyze how novel
compounds of this class affect the cell cycle.
5

2. Chemistry
The synthetic route to 6,7-methylenedioxy-4-substituted phenylquinolin
-2(1H)-one derivatives is illustrated in Scheme 1. The 4-phenylquinolin-2(1H)-one
derivatives 12a-n were prepared using the general Knorr quinoline synthesis
(acid-catalysis).23,24 The synthesis was initiated with alkoxycarbonylation of
substituted acetophenones 8a-n with a diethyl carbonate (9) to provide the
corresponding benzoylacetates 10a-n,25-27 which were condensed with
3,4-methylenedioxy aniline to give benzoylacetanilide intermediates 11a-n. The
4-phenylquinolin-2(1H)-one derivatives 12a-n were obtained by cyclization of key
intermediates 11a-n with excess polyphosphoric acid (PPA) at 100-110 C. The
synthesized compounds 12a-n are reported for the first time. All synthesized
compounds were characterized by IR, 1H NMR, 13C NMR and mass spectrometry. As
an example, the target compound 12a possessed a characteristic peak at 6.02 ppm,
representative of the methylenedioxy protons. Three singlet peaks at 6.18, 6.63 and
6.87 ppm were assignable to C(3)H, C(5)H and C(8)H protons in the 2-quinolone core,
and one broad singlet (11.78 ppm) to an exchangeable NH group. The protons of the
4-phenyl ring appeared in the region 7.36-7.51 ppm. In the 13C NMR spectrum,
compound 12a possessed a characteristic absorption at δ 161.70 ppm for the
2-quinolone amide carbon (NHC=O). The IR spectrum of 12a showed an absorption
at 1653.07 cm-1 for the amide (NHC=O) carbonyl group.
[Scheme 1 should be inserted here]
3. Biological evaluation
3.1. Invitro cytotoxicity assay
6

The newly synthesized analogues 12a-n were evaluated for cytotoxicity against
Detroit 551 normal human cells and eight cancer cell lines: MCF-7 (breast
adenocarcinoma), 2774 (ovarian carcinoma), SKOV-3 (ovarian carcinoma), HL-60
(leukemia), Hep 3B (hepatoma), H460 (non-small-cell-lung carcinoma), COLO205
(colorectal adenocarcinoma) and A498 (renal cell carcinoma). Etoposide and 5-FU
was used as a positive control. The screening procedure was based on the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliun
bromide
(MTT)
growth
inhibition assay, and the results are summarized in Table 1.
Compound 12a, which contains an unsubstituted 4-phenyl E-ring, displayed poor
cytotoxicity with IC50 values from 18.5 to greater than 50 µM. The steric parameters
of hydrogen and fluorine are extremely similar (van der Waals radii of 1.2 Å for
hydrogen vs. 1.35 Å for fluorine), and fluoro-substituted 12l, 12m, and 12n also
displayed weak cytotoxicity against the cancer cell lines.
However, 12k, whose ring E bears the same 3,4,5-trimethoxy substitution found
in PPT, exhibited significant antiproliferative activity with sub-micromolar IC50
(0.93-7.6 μM) against several cancer cell lines. However, potency dropped when the
3,4,5-trimethoxy group (12k) was changed to a 2,4,6-trimethoxy group (12j). In
addition, the effects of dimethoxy substitution on the phenyl E-ring is noteworthy.
Generally, dimethoxy substitution on the 4-phenyl ring (12e, 12f, 12h, 12i) led to
more potent activity than monomethoxy substitution (12b-d). However, compound
12g with 2,6-dimethoxy substitution was less potent than the other four dimethoxy
substituted analogues. Among the four more active dimethoxy compounds, analogue
12e with 2,4-dimethoxy substitution exhibited the most potent anticancer activity
with IC50 less than or equal to 1 μM against five cell lines, 2774 (0.4 μM), SKOV-3
(0.4 μM), HL-60 (0.4 μM), Hep 3B (1.0 μM) and H460 (0.9 μM). Compound 12e was
also generally more potent than the trimethoxy substituted 12k. Modification of the
7

E-ring with different numbers and positions of methoxy substituents may affect its
spatial rotation and the molecular orientation, which could increase binding to the
biological target and anticancer activity of the optimized compounds. Finally, 12e
showed only marginal toxicity against Detroit 551 normal human cells (IC50 ＞ 25
μM). It is also noteworthy that the cell lines more resistant to 12e, including MCF-7,
COLO205, and A498, harbor wild-type p53.
[Table 1 should be inserted here]
It is generally accepted that PPT’s cytotoxicity is attributable to inhibition of
tubulin polymerization, while the target of etoposide is topoisomerase II. Recently, an
alternative non-tubulin and non-antitopoisomerase mode of action has been proposed
for some PPT derivatives. This mechanism is associated with cell death and sub-G1
apoptotic cell accumulation without any significant cell cycle arrest.13 Thus,
mechanistic studies on 12e are underway in our laboratories.
3.2. Morphological changes and apoptosis
Apoptosis is one of the major pathways that lead to the process of cell death.
Chromatin condensation, nuclear shrinking, and fragmented nuclei are known as
classic characteristics of apoptosis. To examine the effect of 12e on apoptotic
induction, the morphology changes of HL-60 and H460 cells were studied using
Hoechst 33258 stain, which confirmed apoptosis as the cause of reduced cell viability.
Compound 12e decreased cell viability and increased morphological changes in
HL-60 and H460 cells. As shown in Figure 4, control cells with 0.1% DMSO
treatment exhibited uniformly dispersed chromatin. Cells treated with compound 12e
for 24 h demonstrated typical apoptotic characteristics, including condensation of
8

chromatin and appearance of nuclear fragmentation and apoptotic bodies (the
arrowhead indicates an apoptotic nucleus). These results clearly demonstrated that the
compound 12e is effective in inducing cellular apoptosis.
[Figure 4 should be inserted here]
3.3. Cell cycle analysis
Previous studies have indicated that PPT analogues induced DNA damage and
caused G2/M arrest.28-30 To evaluate the effect of 12e on the cell cycle andgain further
insight into the mode of action, we examined cell cycle accumulation at 24 h by
propidium iodide staining and flow cytometry quantification in HL-60 and H460 cells
treated with 12e. In HL-60 cells treated with 0.25 μM, 0.5 μM, and 1.0 μM
concentrations of 12e, 11.87%, 25.02% and 40.54%, respectively, of cells were in
G2/M phase, 10.51% of control (untreated) cells were in this phase (Fig. 5A). The
percentage of G2/M cells also increased in H460 cells treated with 12e (Fig. 5B). As
shown in Figure 5, the DNA cell cycle analysis revealed typical G2/M arrest and
apoptosis (a sub-G1 peak appeared) in response to treatment with 12e.
[Figure 5 should be inserted here]
3.4. Mechanism of action
Cyclin B1 and CDK1 are intricately involved in cell cycle progression through
the G2/M phase transition.31 In our previous studies, the exposure of HL-60 cells to
2-PQ analogues led to G2/M phase arrest. In the Western blot analysis, a marked
decrease in the expressions of cyclin B1 and CDK1 were detected in HL-60 cells.32,33
9

As shown in Figure 6, compound 12e induced a transient increase followed by a
decrease in cyclin B1 protein expression, whereas CDK1 protein expression level
decreased in a concentration-dependent manner in HL-60 cells (Fig. 6A). However,
CDK1 protein expression level increased in a concentration-dependent manner in
H460 cells (Fig. 6B). It was reported that treatment with deoxypodophyllotoxin
(DPPT) in Hela cells induced G2/M phase arrest. In the Western blot analysis, cyclin
B1 expression was observed to have a rapid increase within 3 h of DPPT treatment
that remained elevated for up to 24 h. After 48 h, the expression of cyclin B1 returned
to near control levels.34 Another study was reported that treatment of NTUB1 cells
with higher concentration of 1-hydroxy-3-(3-alkylaminopropoxy)-9,10-anthraquinone
(MHA) derivative for 24 h induced up-regulation of cyclinB1 and p21 expressions in
NTUB1 cells while treatment with lower concentration of MHA for 24 h induced
down-regulation of cyclinB1 and up-regulation of p21 expressions in NTUB1 cells.35
These results suggest that cell cycle progression is well regulated by the timing of the
expression of cell-specific cyclins and different concentrations of the compounds.
Apoptosis is associated with activation of caspases, an expanding family of
cysteine proteases that play important roles in the execution phase of apoptosis
triggered by various stimuli.36 Among the capsases, caspase 3 is the best understood
and mediates several apoptotic pathways. As shown in Figure 6, compound 12e
induced caspase 3 cleavage (17 kDa) in HL-60 and H460 cells. The above preliminary
investigation of the mechanism of action of compound 12e suggested that the
anticancer effects of 12e against HL-60 and H460 cells are mediated via G2/M arrest
and caspase-dependent apoptosis.
[Figure 6 should be inserted here]
10

4. Conclusion
4-Phenylquinolin-2(1H)-one derivatives 12a-n were synthesized and tested for
antiproliferative activity against several cancer cell lines. Compound 12e, containing
2,4-dimethoxy substitution on the 4-phenyl ring, demonstrated potent antiproliferative
activities with IC50 values of 0.4, 0.4, 0.4 and 0.9 μM against 2774, SKOV-3, HL-60
and H460, respectively. The significant anticancer activity shown by 12e prompted us
to evaluate cell viability of HL-60 and H460 cells, with the observation of
morphological features of apoptotic cells in these cell lines. Furthermore, 12e could
induce cell cycle arrest in the G2/M phase and apoptosis by activation of caspase-3 in
both HL-60 and H460 cells. In conclusion, among the newly synthesized 4-PQ
derivatives, compound 12e was identified as a promising candidate; due to its
excellent antiproliferative potency, together with remarkable apoptosis-inducing
activity. Further structure optimization of 12e is ongoing.
5. Experimental section
5.1. Materials and physical measurements
All solvents and reagents were obtained commercially and used without further
purification. The progress of all reactions was monitored by TLC on 2 × 6 cm
pre-coated silica gel 60 F254 plates of thickness 0.25 mm (Merck). The chromatograms
were visualized under UV light at 254–366 nm. The following adsorbent was used for
column chromatography: silica gel 60 (Merck, particle size 0.063–0.200 mm).
Melting points (mp) were determined with a Yanaco MP-500D melting point
apparatus and are uncorrected. IR spectra were recorded on Shimadzu IR-Prestige-21
spectrophotometers as KBr pellets. The NMR spectra were obtained on a Bruker
Avance DPX-200 FT-NMR spectrometer at room temperature, and chemical shifts
11

are reported in ppm (δ). The following abbreviations are used: s, singlet; d, doublet; t,
triplet; dd, double doublet; and m, multiplet. Low-resolution mass spectra were
performed by Finnigan/Thermo Qust MAT95XL at National Chung Hsing University,
Taichung, Taiwan.
5.2. Chemistry
5.2.1. General procedure for the synthesis of benzoylacetates 10a-n
The substrate β-ketoesters 10a-n were either purchased or synthesized following
published procedures. Some benzoylacetates were commercially available. Ethyl
3-oxo-3-phenyl propanoate (10a) was purchased. The reaction of benzoylacetates
10b-n was prepared as described in previous reports.25-27 A solution of a substituted
acetophenone 8a-n (0.05 mol) dissolved in toluene (50 mL) was added dropwise to a
solution containing diethyl carbonate (9) (0.10 mol) and sodium hydride (0.15 mol
60% dispersion in mineral oil). The mixture was stirred at room temperature, and then
refluxed for 30 min. The mixture was poured into ice water, acidified with glacial
acetic acid, and extracted with EtOAc (3 × 100 mL). The EtOAc extract was then
dried over anhydrous MgSO4. After removal of the solvent in vacuo, the crude
products were purified by silica gel column chromatography eluting with
dichloromethane to afford benzoylacetates 10b-n. All synthetic compounds were in
agreement with 1H NMR, 13C NMR, IR and mass spectroscopic data.
5.2.1.1. Ethyl 3-(2-methoxyphenyl)-3-oxopropanoate (10b)
Yield 86% from 8b as a yellow liquid; IR (KBr) ν (cm-1): 1735.93, 1674.21
(C=O); 1H NMR (200 MHz, DMSO-d6): δ 1.14 (t, J = 7.2 Hz, 3H, -O-CH2CH3), 3.83
(s, 3H, -OCH3), 3.91 (s, 2H, -CO-CH2-CO-), 4.07 (q, J = 7.2 Hz, 2H, -O-CH2CH3),
7.03 (t, J = 7.6 Hz, 1H, Ar-H), 7.14 (d, J = 8.2 Hz, 1H, Ar-H), 7.56 (t, J = 7.6 Hz, 1H,
Ar-H), 7.70 (d, J = 7.8 Hz, 1H, Ar-H); 13C NMR (50 MHz, DMSO-d6): δ 14.37, 50.48,
12

56.03, 60.80, 112.95, 120.99, 126.11, 130.50, 135.37, 159.37, 168.20, 193.25; MS (EI,
70 eV) m/z: 222.1 (M+); HRMS (EI) m/z: calculated for C12H14O4: 222.0892; found:
222.0884.
5.2.1.2. Ethyl 3-(3-methoxyphenyl)-3-oxopropanoate (10c)
Yield 80% from 8c as a yellow liquid; IR (KBr) ν (cm-1): 1743.65, 1689.64
(C=O); 1H NMR (200 MHz, DMSO-d6): δ 1.16 (t, J = 7.2 Hz, 3H, -O-CH2CH3), 3.80
(s, 3H, -OCH3), 4.06-4.20 (m, 4H, -CO-CH2-CO- and -O-CH2CH3), 7.19-7.25 (m, 1H,
ArH), 7.40-7.57 (m, 3H, ArH); 13C NMR (50 MHz, DMSO-d6): δ 14.36, 46.12, 55.73,
61.05, 113.31, 120.18, 121.34, 130.38, 137.64, 159.91, 168.08, 193.67; MS (EI, 70
eV) m/z: 222.1 (M+); HRMS (EI) m/z: calculated for C12H14O4: 222.0892; found:
222.0898.
5.2.1.3. Ethyl 3-(4-methoxyphenyl)-3-oxopropanoate (10d)
Yield 87% from 8d as a yellow liquid; IR (KBr) ν (cm-1): 1735.93, 1674.21
(C=O); 1H NMR (200 MHz, DMSO-d6): δ 1.16 (t, J = 7.2 Hz, 3H, -O-CH2CH3), 3.82
(s, 3H, -OCH3), 4.05-4.15 (m, 4H, -CO-CH2-CO- and -O-CH2CH3), 7.03 (d, J = 8.9
Hz, 2H, ArH), 7.93 (d, J = 8.9 Hz, 2H, ArH); 13C NMR (50 MHz, DMSO-d6): δ 14.36,
45.71, 55.95, 60.97, 114.40 (2C), 129.24, 131.24 (2C), 164.04, 168.25, 192.06; MS
(EI, 70 eV) m/z: 222.1 (M+); HRMS (EI) m/z: calculated for C12H14O4: 222.0892;
found: 222.0899.
5.2.1.4. Ethyl 3-(2,4-dimethoxyphenyl)-3-oxopropanoate (10e)
Yield 70% from 8e as a yellow liquid; IR (KBr) ν (cm-1): 1735.93, 1666.50
1
(C=O); H NMR (200 MHz, DMSO-d6): δ 1.16 (t, J = 7.2 Hz, 3H, -O-CH2CH3),
3.83-3.84 (m, 8H, 2 × -OCH3 and -CO-CH2-CO-), 4.08 (q, J = 7.2 Hz, 2H,
13
-O-CH2CH3), 6.58-6.62 (m, 2H, ArH), 7.75 (d, J = 9.4 Hz, 1H, ArH); C NMR (50
MHz, DMSO-d6): δ 14.39, 50.42, 56.03 (2C), 60.64, 98.59, 106.83, 119.11, 132.61,
13

161.57, 165.47, 168.46, 190.91; MS (EI, 70 eV) m/z: 252.1 (M+); HRMS (EI) m/z:
calculated for C13H16O5: 252.0998; found: 252.0991.
5.2.1.5. Ethyl 3-(2,5-dimethoxyphenyl)-3-oxopropanoate (10f)
Yield 70% from 8f as a yellow liquid; IR (KBr) ν (cm-1): 1735.93, 1674.21
(C=O); 1H NMR (200 MHz, DMSO-d6): δ 1.16 (t, J = 7.1 Hz, 3H, -O-CH2CH3), 3.73
(s, 3H, -OCH3), 3.80 (s, 3H, -OCH3), 3.91 (s, 2H, -CO-CH2-CO-), 4.08 (q, J = 7.1 Hz,
2H, -O-CH2CH3), 7.12-7.15 (m, 2H, ArH), 7.22-7.24 (m, 1H, ArH); 13C NMR (50
MHz, DMSO-d6): δ 14.38, 50.38, 55.90, 56.42, 60.75, 113.94, 114.51, 121.47, 126.35,
153.40, 153.81, 168.12, 192.75; MS (EI, 70 eV) m/z: 252.2 (M+); HRMS (EI) m/z:
calculated for C13H16O5: 252.0998; found: 252.0996.
5.2.1.6. Ethyl 3-(2,6-dimethoxyphenyl)-3-oxopropanoate (10g)
Yield 78% from 8g as a colorless liquid; IR (KBr) ν (cm-1): 1743.65, 1705.07
(C=O); 1H NMR (200 MHz, DMSO-d6): δ 1.14 (t, J = 7.1 Hz, 3H, -O-CH2CH3), 3.75
(s, 8H, 2 × -OCH3 and -CO-CH2-CO-), 4.06 (q, J = 7.1 Hz, 2H, -O-CH2CH3), 6.70 (d,
J = 8.4 Hz, 2H, ArH), 7.35 (t, J = 8.4 Hz, 1H, ArH); 13C NMR (50 MHz, DMSO-d6):
δ 14.30, 51.47, 56.26 (2C), 60.84, 104.71 (2C), 118.63, 132.07, 156.98 (2C), 166.82,
195.95; MS (EI, 70 eV) m/z: 252.2 (M+); HRMS (EI) m/z: calculated for C13H16O5:
252.0998; found: 252.1006.
5.2.1.7. Ethyl 3-(3,4-dimethoxyphenyl)-3-oxopropanoate (10h)
Yield 76% from 8h as a yellow liquid; IR (KBr) ν (cm-1): 1735.93, 1674.21
(C=O); 1H NMR (200 MHz, DMSO-d6): δ 1.16 (t, J = 7.1 Hz, 3H, -O-CH2CH3), 3.80
(s, 3H, -OCH3), 3.83 (s, 3H, -OCH3), 4.04-4.15 (m, 4H, -CO-CH2-CO- and
-O-CH2CH3), 7.02 (d, J = 8.4 Hz, 1H, ArH), 7.43 (d, J = 1.4 Hz, 1H, ArH), 7.59 (dd, J
= 8.4, 1.2 Hz, 1H, ArH); 13C NMR (50 MHz, DMSO-d6): δ 14.34, 45.62, 55.85, 56.10,
60.98, 110.78, 111.20, 123.85, 129.19, 149.11, 154.03, 168.29, 192.09; MS (EI, 70 eV)
14

m/z: 252.2 (M+); HRMS (EI) m/z: calculated for C13H16O5: 252.0998; found:
252.1003.
5.2.1.8. Ethyl 3-(3,5-dimethoxyphenyl)-3-oxopropanoate (10i)
Yield 81% from 8i as a yellow liquid; IR (KBr) ν (cm-1): 1735.93, 1689.64
(C=O); 1H NMR (200 MHz, DMSO-d6): δ 1.17 (t, J = 7.1 Hz, 3H, -O-CH2CH3), 3.79
(s, 6H, 2 × -OCH3), 4.06-4.15 (m, 4H, -CO-CH2-CO- and -O-CH2CH3), 6.77 (s, 1H,
ArH), 7.07-7.08 (m, 2H, ArH); 13C NMR (50 MHz, DMSO-d6): δ 14.35, 46.16, 55.87
(2C), 61.04, 105.95, 106.57 (2C), 138.21, 161.07 (2C), 168.05, 193.47; MS (EI, 70
eV) m/z: 252.2 (M+); HRMS (EI) m/z: calculated for C13H16O5: 252.0998; found:
252.0994.
5.2.1.9. Ethyl 3-oxo-3-(2,4,6-trimethoxyphenyl)propanoate (10j)
Yield 60% from 8j as a white solid; mp: 69-71 C; IR (KBr) ν (cm-1): 1728.22,
1
1689.64 (C=O); H NMR (200 MHz, DMSO-d6): δ 1.13 (t, J = 7.1 Hz, 3H,
-O-CH2CH3), 3.70 (s, 2H, -CO-CH2-CO-), 3.74 (s, 6H, 2 × -OCH3), 3.80 (s, 3H,
-OCH3), 4.05 (q, J = 7.1 Hz, 2H, -O-CH2CH3), 6.25 (s, 2H, ArH); 13C NMR (50 MHz,
DMSO-d6): δ 14.41, 51.47, 55.95, 56.32 (2C), 60.72, 91.37 (2C), 111.65, 158.81 (2C),
163.17, 167.26, 194.47; MS (EI, 70 eV) m/z: 282.2 (M+); HRMS (EI) m/z: calculated
for C14H18O6: 282.1103; found: 282.1106.
5.2.1.10. Ethyl 3-oxo-3-(3,4,5-trimethoxyphenyl)propanoate (10k)
Yield 69% from 8k as a colorless liquid; IR (KBr) ν (cm-1): 1743.65, 1681.93
(C=O); 1H NMR (200 MHz, DMSO-d6): δ 1.18 (t, J = 7.1 Hz, 3H, -O-CH2CH3), 3.75
(s, 3H, -OCH3), 3.84 (s, 6H, 2 × -OCH3), 4.07-4.19 (m, 4H, -CO-CH2-CO- and
-O-CH2CH3), 7.25 (s, 2H, ArH); 13C NMR (50 MHz, DMSO-d6): δ 14.36, 45.88,
56.41 (2C), 60.52, 61.01, 106.46 (2C), 131.51, 142.82, 153.24 (2C), 168.18, 192.68;
MS (EI, 70 eV) m/z: 282.2 (M+); HRMS (EI) m/z: calculated for C14H18O6: 282.1103;
15

found: 282.1102.
5.2.1.11. Ethyl 3-(2-fluorophenyl)-3-oxopropanoate (10l)
Yield 73% from 8l as a yellow liquid; IR (KBr) ν (cm-1): 1743.65, 1689.64
1
(C=O); H NMR (200 MHz, DMSO-d6): δ 1.15 (t, J = 7.1 Hz, 3H, -O-CH2CH3),
4.04-4.15 (m, 4H, -CO-CH2-CO- and -O-CH2CH3), 7.29-7.39 (m, 2H, ArH),
13
7.64-7.72 (m, 1H, ArH), 7.82-7.87 (m, 1H, ArH); C NMR (50 MHz, DMSO-d6): δ
14.36, 49.52 (d, 4JCF = 6.0 Hz, 1C), 61.09, 117.33 (d, 2JCF = 23.0 Hz, 1C), 124.77 (d,
3
1
2JCF = 11.5 Hz, 1C), 125.33, 130.89, 136.27 (d, JCF = 9.0 Hz, 1C), 161.74 (d, JCF
=
253.0 Hz, 1C), 167.76, 191.09; MS (EI, 70 eV) m/z: 210.1 (M+); HRMS (EI) m/z:
calculated for C11H11FO3: 210.0692; found: 210.0700.
5.2.1.12. Ethyl 3-(3-fluorophenyl)-3-oxopropanoate (10m)
Yield 69% from 8m as a yellow liquid; IR (KBr) ν (cm-1): 1743.65, 1689.64
(C=O); 1H NMR (200 MHz, DMSO-d6): δ 1.16 (t, J = 7.1 Hz, 3H, -O-CH2CH3), 4.11
(q, J = 7.1 Hz, 2H, -O-CH2CH3), 4.20 (s, 2H, -CO-CH2-CO-), 7.46-7.64 (m, 2H, ArH),
7.68-7.83 (m, 2H, ArH); 13C NMR (50 MHz, DMSO-d6): δ 14.36, 46.08, 61.13,
115.35 (d, 2JCF = 22.5 Hz, 1C), 121.12 (d, 2JCF = 21.5 Hz, 1C), 125.06, 131.45 (d, 3JCF
= 8.0 Hz, 1C), 138.45 (d, 3JCF = 6.5 Hz, 1C), 162.64 (d, 1JCF = 244.0 Hz, 1C), 167.90,
193.00; MS (EI, 70 eV) m/z: 210.1 (M+); HRMS (EI) m/z: calculated for C11H11FO3:
210.0692; found: 210.0695.
5.2.1.13. Ethyl 3-(4-fluorophenyl)-3-oxopropanoate (10n)
Yield 77% from 8n as a yellow liquid; IR (KBr) ν (cm-1): 1743.65, 1689.64
(C=O); 1H NMR (200 MHz, DMSO-d6): δ 1.16 (t, J = 7.1 Hz, 3H, -O-CH2CH3), 4.10
(q, J = 7.1 Hz, 2H, -O-CH2CH3), 4.17 (s, 2H, -CO-CH2-CO-), 7.30-7.39 (m, 2H, ArH),
8.00-8.07 (m, 2H, ArH); 13C NMR (50 MHz, DMSO-d6): δ 14.36, 45.94, 61.08,
116.28 (d, 2JCF = 21.9 Hz, 2C), 131.43 (d, 3JCF = 9.6 Hz, 2C), 133.05, 165.80 (d, 1JCF
16

= 251.0 Hz, 1C), 168.01, 192.53; MS (EI, 70 eV) m/z: 210.1 (M+); HRMS (EI) m/z:
calculated for C11H11FO3: 210.0692; found: 210.0701.
5.2.2. General procedure for the synthesis of benzoylacetanilides 11a-n
A mixture of the substituted benzoylacetate (10a-n, 1 equiv) and
3,4-methylenedioxy aniline (1 equiv) was stirred in 150 mL toluene and then heated at
reflux for 1-2 h. The mixture was cooled to the room temperature and partitioned with
10% NaOH (3 × 50 mL). The aqueous layer was acidified to pH 4-5 with dropwise
addition of glacial acetic acid. The resulting precipitate was isolated by suction
filtration, washed with water and EtOH, and then air-dried air to give the desired
benzoylacetanilide (11a-n) of sufficient purity for the next reaction.
5.2.2.1. N-(Benzo[d][1,3]dioxol-5-yl)-3-oxo-3-phenylpropanamide (11a)
Yield 45% from 10a as a light-yellow solid; mp: 149-151 C; IR (KBr) ν (cm-1):
1654.03, 1684.89 (C=O); 1H NMR (200 MHz, DMSO-d6): δ 4.09 (s, 2H, -CH2-), 5.97
(s, 2H, -O-CH2-O-), 6.84 (d, J = 8.4 Hz, 1H, ArH), 6.94 (dd, J = 8.4, 2.0 Hz, 1H,
ArH), 7.28 (d, J = 2.0 Hz, 1H, ArH), 7.51-7.58 (m, 2H, ArH), 7.63-7.74 (m, 1H, ArH),
13
8.00 (d, J = 7.2 Hz, 1H, ArH), 10.11 (s, 1H, NH); C NMR (50 MHz, DMSO-d6): δ
48.41, 101.43, 101.67, 108.53, 112.33, 128.81 (2C), 129.25 (2C), 133.83, 134.03,
136.72, 143.45, 147.53, 165.39, 195.04; MS (EI, 70 eV) m/z: 283.2 (M+); HRMS (EI)
m/z: calculated for C16H13NO4: 283.0845; found: 283.0836.
5.2.2.2. N-(Benzo[d][1,3]dioxol-5-yl)-3-(2-methoxyphenyl)-3-oxopropanamide
(11b)
Yield 38% from 10b as a white solid; mp: 143-144 C; IR (KBr) ν (cm-1):
1
1656.92, 1672.36 (C=O); H NMR (200 MHz, DMSO-d6): δ 3.85 (s, 3H, -OCH3),
3.97 (s, 2H, -CH2-), 5.96 (s, 2H, -O-CH2-O-), 6.83 (d, J = 8.4 Hz, 1H, ArH), 6.94 (dd,
J = 8.4, 1.6 Hz, 1H, ArH), 7.04 (t, J = 7.4 Hz, 1H, ArH), 7.15 (d, J = 8.2 Hz, 1H,
17

ArH), 7.28 (d, J = 1.6 Hz, 1H, ArH), 7.56 (t, J = 7.8 Hz, 1H, ArH), 7.69 (d, J = 7.7
Hz, 1H, ArH), 10.01 (s, 1H, NH); 13C NMR (50 MHz, DMSO-d6): δ 52.96, 56.23,
101.39, 101.65, 108.51, 112.23, 113.01, 120.94, 126.91, 130.45, 133.99, 134.96,
143.29, 147.49, 159.23, 165.82, 195.04; MS (EI, 70 eV) m/z: 313.2 (M+); HRMS (EI)
m/z: calculated for C17H15NO5: 313.0950; found: 313.0959.
5.2.2.3. N-(Benzo[d][1,3]dioxol-5-yl)-3-(3-methoxyphenyl)-3-oxopropanamide
(11c)
Yield 37% from 10c as a pale gray solid; mp: 141-142 C; IR (KBr) ν (cm-1):
1
1656.92, 1685.86 (C=O); H NMR (200 MHz, DMSO-d6): δ 3.81 (s, 3H, -OCH3),
4.08 (s, 2H, -CH2-), 5.97 (s, 2H, -O-CH2-O-), 6.84 (d, J = 8.4 Hz, 1H, ArH), 6.93 (dd,
J = 8.4, 1.8 Hz, 1H, ArH), 7.21-7.50 (m, 4H, ArH), 7.59 (d, J = 7.6 Hz, 1H, ArH),
13
10.12 (s, 1H, NH); C NMR (50 MHz, DMSO-d6): δ 48.57, 55.84, 101.44, 101.68,
108.53, 112.34, 113.36, 119.98, 121.34, 130.43, 133.81, 138.11, 143.46, 147.54,
159.91, 165.35, 194.79; MS (EI, 70 eV) m/z: 313.2 (M+); HRMS (EI) m/z: calculated
for C17H15NO5: 313.0950; found: 313.0958.
5.2.2.4. N-(Benzo[d][1,3]dioxol-5-yl)-3-(4-methoxyphenyl)-3-oxopropanamide
(11d)
Yield 38% from 10d as a light-brown solid; mp: 144-145 C; IR (KBr) ν (cm-1):
1
1655.96, 1674.28 (C=O); H NMR (200 MHz, DMSO-d6): δ 3.84 (s, 3H, -OCH3),
4.02(s, 2H, -CH2-), 5.97 (s, 2H, -O-CH2-O-), 6.84 (d, J = 8.4 Hz, 1H, ArH), 6.93 (dd,
J = 8.4, 1.8 Hz, 1H, ArH), 7.06 (d, J = 8.8 Hz, 2H, ArH), 7.27 (d, J = 1.6 Hz, 1H,
ArH), 7.97 (d, J = 8.8 Hz, 2H, ArH), 10.09 (s, 1H, NH); 13C NMR (50 MHz,
DMSO-d6): δ 48.15, 56.06, 101.42, 101.64, 108.52, 112.30, 114.45 (2C), 129.70,
131.23 (2C), 133.87, 143.40, 147.50, 163.89, 165.57, 193.34; MS (EI, 70 eV) m/z:
313.1 (M+); HRMS (EI) m/z: calculated for C17H15NO5: 313.0950; found: 313.0944.
18

5.2.2.5. N-(Benzo[d][1,3]dioxol-5-yl)-3-(2,4-dimethoxyphenyl)-3-oxopropanami
de (11e)
Yield 44 % from 10e as a white solid; mp: 164-166 C; IR (KBr) ν (cm-1):
1
1652.10, 1676.21 (C=O); H NMR (200 MHz, DMSO-d6): δ 3.83 (s, 3H, -OCH3),
3.85 (s, 3H, -OCH3), 3.89 (s, 2H, -CH2-), 5.96 (s, 2H, -O-CH2-O-), 6.61-6.64 (m, 2H,
ArH), 6.83 (d, J = 8.4 Hz, 1H, ArH), 6.93 (dd, J = 8.4, 1.8 Hz, 1H, ArH), 7.27 (d, J =
13
1.6 Hz, 1H, ArH), 7.73 (d, J = 9.4 Hz, 1H, ArH), 9.96 (s, 1H, NH); C NMR (50
MHz, DMSO-d6): δ 52.90, 56.13, 56.29, 98.76, 101.36, 101.60, 106.78, 108.50,
112.16, 119.73, 132.62, 134.09, 143.21, 147.48, 161.52, 165.20, 166.19, 192.68; MS
(EI, 70 eV) m/z: 343.2 (M+); HRMS (EI) m/z: calculated for C18H17NO6: 343.1056;
found: 343.1049.
5.2.2.6. N-(Benzo[d][1,3]dioxol-5-yl)-3-(2,5-dimethoxyphenyl)-3-oxopropanami
de (11f)
Yield 48% from 10f as a light-brown solid; mp: 144-146 C; IR (KBr) ν (cm-1):
1646.32, 1668.50 (C=O); 1H NMR (200 MHz, CDCl3-d1): δ 3.73 (s, 3H, -OCH3), 3.80
(s, 3H, -OCH3), 3.95(s, 2H, -CH2-), 5.96 (s, 2H, -O-CH2-O-), 6.83 (d, J = 8.6 Hz, 1H,
ArH), 6.89-6.95 (m, 1H, ArH), 7.08-7.31 (m, 4H, ArH), 10.00 (s, 1H, NH); 13C NMR
(50 MHz, CDCl3-d1): δ 52.88, 56.00, 56.68, 101.38, 101.61, 108.53, 112.19, 114.04,
114.61, 121.01, 127.11, 133.98, 143.27, 147.49, 153.34, 153.65, 165.80, 194.58; MS
(EI, 70 eV) m/z: 343.2 (M+); HRMS (EI) m/z: calculated for C18H17NO6: 343.1056;
found: 343.1051.
5.2.2.7. N-(Benzo[d][1,3]dioxol-5-yl)-3-(2,6-dimethoxyphenyl)-3-oxopropanami
de (11g)
Yield 59% from 10g as a white solid; mp: 131-133 C; IR (KBr) ν (cm-1):
1
1654.03, 1709.97 (C=O); H NMR (200 MHz, DMSO-d6): δ 3.72 (s, 6H, -OCH3),
19

3.74 (s, 2H, -CH2-), 5.96 (s, 2H, -O-CH2-O-), 6.69 (d, J = 8.4 Hz, 2H, ArH), 6.82 (d, J
= 8.4 Hz, 1H, ArH), 6.92 (dd, J = 8.4, 1.8 Hz, 1H, ArH), 7.25 (d, J = 1.8 Hz, 1H,
ArH), 7.33 (t, J = 8.4 Hz, 1H, ArH), 9.94 (s, 1H, NH); 13C NMR (50 MHz, DMSO-d6):
δ 53.89, 56.36 (2C), 101.40,101.76, 104.81 (2C), 108.46, 112.43, 119.26, 131.84,
133.89, 143.37, 147.44, 156.95 (2C), 164.02, 197.56; MS (EI, 70 eV) m/z: 342.9 (M+);
HRMS (EI) m/z: calculated for C18H17NO6: 343.1056; found: 343.1062.
5.2.2.8. N-(Benzo[d][1,3]dioxol-5-yl)-3-(3,4-dimethoxyphenyl)-3-oxopropanami
de (11h)
Yield 39% from 10h as a pale gray solid; mp: 191-192 C; IR (KBr) ν (cm-1):
1
1653.07, 1676.21 (C=O); H NMR (200 MHz, DMSO-d6): δ 3.80 (s, 3H, -OCH3),
3.84 (s, 3H, -OCH3), 4.03(s, 2H, -CH2-), 5.96 (s, 2H, -O-CH2-O-), 6.84 (d, J = 8.4 Hz,
1H, ArH), 6.94 (dd, J = 8.3, 1.8 Hz, 1H, ArH), 7.08 (d, J = 8.4 Hz, 1H, ArH), 7.27 (d,
J = 1.6 Hz, 1H, ArH), 7.47 (d, J = 1.6 Hz, 1H, ArH), 7.67 (dd, J = 8.4, 1.8 Hz, 1H,
ArH), 10.12 (s, 1H, NH); 13C NMR (50 MHz, DMSO-d6): δ 48.15, 56.01, 56.25,
101.43, 101.65, 108.52, 110.90, 111.39, 112.30, 123.86, 129.67, 133.88, 143.42,
147.52, 149.08, 153.86, 165.57, 193.34; MS (EI, 70 eV) m/z: 343.1 (M+); HRMS (EI)
m/z: calculated for C18H17NO6: 343.1056; found: 343.1050.
5.2.2.9. N-(Benzo[d][1,3]dioxol-5-yl)-3-(3,5-dimethoxyphenyl)-3-oxopropanami
de (11i)
Yield 61% from 10i as a light-brown solid; mp: 158-160 C; IR (KBr) ν (cm-1):
1
1653.07, 1695.50 (C=O); H NMR (200 MHz, DMSO-d6): δ 3.79 (s, 6H, -OCH3),
4.06 (s, 2H, -CH2-), 5.97 (s, 2H, -O-CH2-O-), 6.77-6.86 (m, 2H, ArH), 6.92 (dd, J =
8.4, 2.0 Hz, 1H, ArH), 7.10 (d, J = 2.2 Hz, 2H, ArH), 7.26 (d, J = 2.0 Hz, 1H, ArH),
10.12 (s, 1H, NH); 13C NMR (50 MHz, DMSO-d6): δ 48.65, 56.03 (2C), 101.44,
101.64, 105.80, 106.60 (2C), 108.56, 112.31, 133.78, 138.67, 143.46, 147.53, 161.08
20

(2C), 165.30, 194.59; MS (EI, 70 eV) m/z: 342.9 (M+); HRMS (EI) m/z: calculated for
C18H17NO6: 343.1056; found: 343.1059.
5.2.2.10. N-(Benzo[d][1,3]dioxol-5-yl)-3-oxo-3-(2,4,6-trimethoxyphenyl)propana
mide (11j)
Yield 51% from 10j as a white solid; mp: 124-126 C; IR (KBr) ν (cm-1):
1652.10, 1706.11 (C=O); 1H NMR (200 MHz, DMSO-d6): δ 3.69 (s, 2H, -CH2-), 3.72
(s, 6H, -OCH3), 3.79 (s, 3H, -OCH3), 5.96 (s, 2H, -O-CH2-O-), 6.24 (s, 2H, ArH),
6.82 (d, J = 8.4 Hz, 1H, ArH), 6.92 (dd, J = 8.4, 1.8 Hz, 1H, ArH), 7.25 (d, J = 1.8 Hz,
13
1H, ArH), 9.90 (s, 1H, NH); C NMR (50 MHz, DMSO-d6): δ 53.90, 55.95, 56.36
(2C), 91.41 (2C), 101.38, 101.69, 108.46, 112.33 (2C), 133.96, 143.29, 147.42,
158.72 (2C), 162.91, 164.57, 197.17; MS (EI, 70 eV) m/z: 372.6 (M+); HRMS (EI)
m/z: calculated for C19H19NO7: 373.1162; found: 373.1166.
5.2.2.11. N-(Benzo[d][1,3]dioxol-5-yl)-3-oxo-3-(3,4,5-trimethoxyphenyl)propana
mide (11k)
Yield 27% from 10k as a white solid; mp: 186-188 C; IR (KBr) ν (cm-1):
1
1649.21, 1672.36 (C=O); H NMR (200 MHz, DMSO-d6): δ 3.74 (s, 3H, -OCH3),
3.83 (s, 6H, -OCH3), 4.08 (s, 2H, -CH2-), 5.97 (s, 2H, -O-CH2-O-), 6.84 (d, J = 8.4 Hz,
1H, ArH), 6.93 (dd, J = 8.4, 2.0 Hz, 1H, ArH), 7.26-7.29 (m, 3H, ArH), 10.16 (s, 1H,
NH); 13C NMR (50 MHz, DMSO-d6): δ 48.42, 56.59 (2C), 60.65, 101.45, 101.67,
106.48 (2C), 108.56, 112.36, 131.98, 133.76, 142.65, 143.47, 147.53, 153.25 (2C),
165.46, 193.82; MS (EI, 70 eV) m/z: 373.0 (M+); HRMS (EI) m/z: calculated for
C19H19NO7: 373.1162; found: 373.1170.
5.2.2.12. N-(Benzo[d][1,3]dioxol-5-yl)-3-(2-fluorophenyl)-3-oxopropanamide
(11l)
Yield 61% from 10l as a white solid; mp: 147-148 C; IR (KBr) ν (cm-1):
21

1
1653.07, 1691.64 (C=O); H NMR (200 MHz, CDCl3-d1): δ 4.10 (d, J = 2.4 Hz, 2H,
-CH2-), 5.93 (s, 2H, -O-CH2-O-), 6.73 (d, J = 8.2 Hz, 1H, ArH), 6.86 (dd, J = 8.2, 2.2
Hz, 1H, ArH), 7.11-7.22 (m, 2H, ArH), 7.26 (d, J = 2.2 Hz, 1H, ArH), 7.53-7.60 (m,
1H, ArH), 7.84-7.92 (m, 1H, ArH), 9.00 (s, 1H, NH); 13C NMR (50 MHz, CDCl3-d1):
2
δ 49.45 (d, 4JCF = 8.0 Hz, 1C), 101.27, 103.11, 108.05, 113.51, 117.01 (d, JCF = 23.0
Hz, 1C), 124.56 (d, 2JCF = 21.5 Hz, 1C), 124.77, 130.75, 131.79, 135.84 (d, 3JCF = 9.5
Hz, 1C), 144.46, 147.79, 161.98 (d, 1JCF = 254.5 Hz, 1C), 163.62, 194.75; MS (EI, 70
eV) m/z: 301.0 (M+); HRMS (EI) m/z: calculated for C16H12FNO4: 301.0750; found:
301.0760.
5.2.2.13. N-(Benzo[d][1,3]dioxol-5-yl)-3-(3-fluorophenyl)-3-oxopropanamide
(11m)
Yield 62% from 10m as a pale gray solid; mp: 130-132 C; IR (KBr) ν (cm-1):
1655.96, 1695.50 (C=O); 1H NMR (200 MHz, DMSO-d6): δ 4.10 (s, 2H, -CH2-), 5.96
(s, 2H, -O-CH2-O-), 6.84 (d, J = 8.4 Hz, 1H, ArH), 6.92 (dd, J = 8.4, 1.8 Hz, 1H, ArH),
7.25 (d, J = 1.8 Hz, 1H, ArH), 7.51-7.86 (m, 4H, ArH), 10.13 (s, 1H, NH); 13C NMR
(50 MHz, DMSO-d6): δ 48.51, 101.41, 101.71, 108.56, 112.35, 115.31 (d, 2JCF = 22.5
2
Hz, 1C), 120.94 (d, JCF = 21.0 Hz, 1C), 125.09, 131.39, 133.75, 138.88, 143.48,
1
147.55, 162.69 (d, JCF = 244.0 Hz, 1C), 165.13, 194.09; MS (EI, 70 eV) m/z: 300.9
(M+); HRMS (EI) m/z: calculated for C16H12FNO4: 301.0750; found: 301.0747.
5.2.2.14. N-(Benzo[d][1,3]dioxol-5-yl)-3-(4-fluorophenyl)-3-oxopropanamide
(11n)
Yield 59% from 10n as a white solid; mp: 164-165 C; IR (KBr) ν (cm-1):
1633.78, 1690.68 (C=O); 1H NMR (200 MHz, DMSO-d6): δ 4.09 (s, 2H, -CH2-), 5.96
(s, 2H, -O-CH2-O-), 6.83 (d, J = 8.4 Hz, 1H, ArH), 6.93 (dd, J = 8.4, 1.8 Hz, 1H, ArH),
7.27 (d, J = 1.8 Hz, 1H, ArH), 7.32-7.41 (m, 2H, ArH), 8.04-8.11 (m, 2H, ArH), 10.11
22

(s, 1H, NH); 13C NMR (50 MHz, DMSO-d6): δ 48.36, 101.44, 101.68, 108.53, 112.35,
116.29 (d, 2JCF = 21.5 Hz, 2C), 131.90 (d, 3JCF = 9.5 Hz, 2C), 133.47, 133.77, 143.47,
1
147.53, 165.30, 165.69 (d, JCF = 250.5 Hz, 1C), 193.71; MS (EI, 70 eV) m/z: 300.9
(M+); HRMS (EI) m/z: calculated for C16H12FNO4: 301.0750; found: 301.0755.
5.2.3. General procedure for the synthesis of 6,7-methylenedioxy-4-substituted
phenylquinolin-2-one derivatives 12a-n
A mixture of the benzoylacetanilide (11a-n) and PPA (10 g) was heated at
100-110 C for 0.5 h to 1 h. The mixture was cooled after TLC monitoring indicated
that the reaction was completed, and then the reaction mixture diluted with ice water,
and extracted with CHCl3 (3 × 50 mL). The combined organic layers were dried over
anhydrous MgSO4, and the solvent was removed in vacuo. The crude products were
purified by column chromatography (silica gel, chloroform/ethyl acetate = 2/1) to
give the corresponding pure 4-phenylquinolin-2-ones 12a-n.
5.2.3.1. 6,7-Methylenedioxy-4-phenylquinolin-2(1H)-one (12a)
Compound 12a (0.16 g, 0.60 mmol) was obtained by cyclization of 11a (0.27 g,
0.95 mmol) with PPA (10 g); Yield: 63%; white solid; mp: 274-275 C; IR (KBr) ν
1
(cm-1): 1653.07 (C=O); H NMR (200 MHz, DMSO-d6): δ 6.02 (s, 2H, -O-CH2-O-),
6.18 (s, 1H, Ar-H), 6.63 (s, 1H, Ar-H), 6.87 (s, 1H, Ar-H), 7.36-7.51 (m, 5H, Ar-H),
11.78 (br. s, 1H, NH); 13C NMR (50 MHz, CDCl3-d1): δ 45.27, 101.25, 103.00,
108.04, 113.43, 128.57 (2C), 128.95 (2C), 131.81, 134.34, 136.05, 144.42, 147.76,
163.61, 196.51; MS (EI, 70 eV) m/z: 265.1 (M+); HRMS (EI) m/z: calculated for
C16H11NO3: 265.0739; found: 265.0733.
5.2.3.2. 6,7-Methylenedioxy-4-(2-methoxyphenyl)quinolin-2(1H)-one (12b)
Compound 12b (0.19 g, 0.64 mmol) was obtained by cyclization of 11b (0.29 g,
0.93 mmol) with PPA (10 g); Yield: 68%; white solid; mp: 269-271 C; IR (KBr) ν
23

(cm-1): 1663.07 (C=O); 1H NMR (200 MHz, DMSO-d6): δ 3.65 (s, 3H, -OCH3), 5.99,
6.01 (s, each 1H, -O-CH2-O-), 6.13 (s, 1H, Ar-H), 6.30 (s, 1H, Ar-H), 6.84 (s, 1H,
Ar-H), 7.02 (t, J = 7.4 Hz, 1H, Ar-H), 7.10-7.17 (m, 2H, Ar-H), 7.43 (t, J = 7.4 Hz, 1H,
Ar-H), 11.71 (br. s, 1H, NH); 13C NMR (50 MHz, DMSO-d6): δ 55.89, 95.79, 102.26,
103.90, 112.00, 113.69, 119.44, 121.17, 126.27, 130.37, 130.77, 136.09, 143.71,
149.69, 150.35, 156.41, 161.85; MS (EI, 70 eV) m/z: 295.1 (M+); HRMS (EI) m/z:
calculated for C17H13NO4: 295.0845; found: 295.0835.
5.2.3.3. 6,7-Methylenedioxy-4-(3-methoxyphenyl)quinolin-2(1H)-one (12c)
Compound 12c (0.17 g, 0.58 mmol) was obtained by cyclization of 11c (0.30 g,
0.96 mmol) with PPA (10 g); Yield: 60%; white solid; mp: 278-279 C; IR (KBr) ν
(cm-1): 1653.07 (C=O); 1H NMR (200 MHz, DMSO-d6): δ 3.75 (s, 3H, -OCH3), 6.02
(s, 2H, -O-CH2-O-), 6.19 (s, 1H, Ar-H), 6.66 (s, 1H, Ar-H), 6.85 (s, 1H, Ar-H),
6.90-6.93 (m, 2H, Ar-H), 7.00 (dd, J = 8.2, 2.2 Hz, 1H, Ar-H), 7.38 (t, J = 8.2 Hz, 1H,
Ar-H), 11.73 (br. s, 1H, NH); 13C NMR (50 MHz, DMSO-d6): δ 55.65, 96.01, 102.38,
103.75, 112.87, 114.37, 114.75 118.75, 121.09, 130.23, 136.79, 138.98, 143.78,
150.49, 151.57, 159.80, 161.62; MS (EI, 70 eV) m/z: 295.2 (M+); HRMS (EI) m/z:
calculated for C17H13NO4: 295.0845; found: 295.0851.
5.2.3.4. 6,7-Methylenedioxy-4-(4-methoxyphenyl)quinolin-2(1H)-one (12d)
Compound 12d (0.19 g, 0.64 mmol) was obtained by cyclization of 11d (0.29 g,
0.93 mmol) with PPA (10 g); Yield: 68%; white solid; mp: 269-271 C; IR (KBr) ν
(cm-1): 1663.07 (C=O); 1H NMR (200 MHz, DMSO-d6): δ 3.82 (s, 3H, -OCH3), 6.06
(s, 2H, -O-CH2-O-), 6.19 (s, 1H, Ar-H), 6.75 (s, 1H, Ar-H), 6.90 (s, 1H, Ar-H), 7.07 (d,
J = 8.6 Hz, 1H, Ar-H), 7.37 (d, J = 8.6 Hz, 1H, Ar-H), 11.69 (br. s, 1H, NH); 13C
NMR (50 MHz, DMSO-d6): δ 55.70, 96.06, 102.37, 103.86, 113.13, 114.64 (2C),
118.60, 129.76, 130.32 (2C), 136.81, 143.82, 150,46, 151.53, 160.04, 161.73; MS (EI,
24

70 eV) m/z: 295.2 (M+); HRMS (EI) m/z: calculated for C17H13NO4: 295.0845; found:
295.0851.
5.2.3.5. 6,7-Methylenedioxy-4-(2,4-dimethoxyphenyl)quinolin-2(1H)-one (12e)
Compound 12e (0.11 g, 0.34 mmol) was obtained by cyclization of 11e (0.19 g,
0.55 mmol) with PPA (10 g); Yield: 61%; white solid; mp: 251-252 C; IR (KBr) ν
(cm-1): 1654.03 (C=O); 1H NMR (200 MHz, DMSO-d6): δ 3.67 (s, 3H, -OCH3), 3.81
(s, 3H, -OCH3), 6.02, 6.04 (s, each 1H, -O-CH2-O-), 6.12 (s, 1H, Ar-H), 6.39 (s, 1H,
Ar-H), 6.61-6.69 (m, 2H, Ar-H), 6.85 (s, 1H, Ar-H), 7.09 (d, J = 8.2 Hz, 1H, Ar-H),
13
11.70 (br. s, 1H, NH); C NMR (50 MHz, DMSO-d6): δ 55.79, 55.95, 95.76, 99.16,
102.24, 104.07, 105.74, 114.07, 118.73, 119.56, 131.07, 135.98, 143.69, 149.72,
150.28, 157.53, 161.57, 161.99; MS (EI, 70 eV) m/z: 325.1 (M+); HRMS (EI) m/z:
calculated for C18H15NO5: 325.0950; found: 325.0954.
5.2.3.6. 6,7-Methylenedioxy-4-(2,5-dimethoxyphenyl)quinolin-2(1H)-one (12f)
Compound 12f (0.10 g, 0.31 mmol) was obtained by cyclization of 11f (0.17 g,
0.50 mmol) with PPA (10 g); Yield: 62%; white solid; mp: 240-241 C; IR (KBr) ν
(cm-1): 1669.46 (C=O); 1H NMR (200 MHz, DMSO-d6): δ 3.59 (s, 3H, -OCH3), 3.69
(s, 3H, -OCH3), 5.99, 6.02 (s, each 1H, -O-CH2-O-), 6.14 (s, 1H, Ar-H), 6.33 (s, 1H,
Ar-H), 6.74 (d, J = 2.8 Hz, 1H, Ar-H), 6.84 (s, 1H, Ar-H), 6.98 (dd, J = 8.9, 2.8 Hz,
1H, Ar-H), 7.06 (d, J = 9.2 Hz, 1H, Ar-H), 11.71 (br. s, 1H, NH); 13C NMR (50 MHz,
DMSO-d6): δ 55.94, 56.38, 95.77, 102.27, 103.96, 113.22, 113.60, 115.31, 116.03,
119.38, 127.04, 136.06, 143.73, 149.50, 150.39 (2C), 153.61, 161.85; MS (EI, 70 eV)
m/z: 325.2 (M+); HRMS (EI) m/z: calculated for C18H15NO5: 325.0950; found:
325.0959.
5.2.3.7. 6,7-Methylenedioxy-4-(2,6-dimethoxyphenyl)quinolin-2(1H)-one (12g)
Compound 12g (0.49 g, 1.51 mmol) was obtained by cyclization of 11g (0.75 g,
25

2.18 mmol) with PPA (10 g); Yield: 69%; white solid; mp: 280-281 C; IR (KBr) ν
1
(cm-1): 1654.03 (C=O); H NMR (200 MHz, CDCl3-d1): δ 3.68 (s, 6H, 2 × -OCH3),
5.93 (s, 2H, -O-CH2-O-), 6.48 (s, 2H, Ar-H), 6.65 (d, J = 8.4 Hz, 2H, Ar-H), 6.99 (s,
1H, Ar-H), 7.35 (t, J = 8.4 Hz, 1H, Ar-H), 12.99 (br. s, 1H, NH); 13C NMR (50 MHz,
CDCl3-d1): δ 55.91 (2C), 96.48, 101.53, 103.72, 104.05 (2C), 114.71, 115.38, 119.94,
130.12, 135.68, 144.23, 146.92, 150.38, 157.62 (2C), 164.53; MS (EI, 70 eV) m/z:
325.3 (M+); HRMS (EI) m/z: calculated for C18H15NO5: 325.0950; found: 325.0954.
5.2.3.8. 6,7-Methylenedioxy-4-(3,4-dimethoxyphenyl)quinolin-2(1H)-one (12h)
Compound 12h (2.29 g, 7.04 mmol) was obtained by cyclization of 11h (3.00 g,
8.74 mmol) with PPA (10 g); Yield: 80%; white solid; mp: 272-273 C; IR (KBr) ν
(cm-1): 1647.28 (C=O); 1H NMR (200 MHz, DMSO-d6): δ 3.77 (s, 3H, -OCH3), 3.80
(s, 3H, -OCH3), 6.05 (s, 2H, -O-CH2-O-), 6.23 (s, 1H, Ar-H), 6.81 (s, 1H, Ar-H), 6.88
(s, 1H, Ar-H), 6.93 (dd, J = 8.2, 1.8 Hz, 1H, Ar-H), 6.98 (d, J = 1.8 Hz, Ar-H), 7.06 (d,
J = 8.2 Hz, 1H, Ar-H), 11.73 (br. s, 1H, NH); 13C NMR (50 MHz, DMSO-d6): δ 56.00
(2C), 96.00, 102.33, 103.94, 112.15, 112.61, 113.14, 118.59, 121.35, 129.97, 136.74,
143.78, 149.17, 149.56, 150.41, 151.71, 161.76; MS (EI, 70 eV) m/z: 325.1 (M+);
HRMS (EI) m/z: calculated for C18H15NO5: 325.0950; found: 325.0954.
5.2.3.9. 6,7-Methylenedioxy-4-(3,5-dimethoxyphenyl)quinolin-2(1H)-one (12i)
Compound 12i (0.41 g, 1.26 mmol) was obtained by cyclization of 11i (0.75 g,
2.18 mmol) with PPA (10 g); Yield: 57%; white solid; mp: 283-284 C; IR (KBr) ν
1
(cm-1): 1654.03 (C=O); H NMR (200 MHz, DMSO-d6): δ 3.74 (s, 6H, 2 × -OCH3),
6.03 (s, 2H, -O-CH2-O-), 6.20 (s, 1H, Ar-H), 6.49-6.57 (m, 3H, Ar-H), 6.71 (s, 1H,
13
Ar-H), 6.86 (s, 1H, Ar-H), 11.73 (br. s, 1H, NH); C NMR (50 MHz, DMSO-d6): δ
55.83 (2C), 96.00, 100.87, 102.38, 103.79, 106.96 (2C), 112.87, 118.56, 136.73,
139.59, 143.82, 150.54, 151.70, 160.97 (2C), 161.64; MS (EI, 70 eV) m/z: 325.2 (M+);
26

HRMS (EI) m/z: calculated for C18H15NO5: 325.0950; found: 325.0954.
5.2.3.10. 6,7-Methylenedioxy-4-(2,4,6-trimethoxyphenyl)quinolin-2(1H)-one
(12j)
Compound 12j (0.12 g, 0.34 mmol) was obtained by cyclization of 11j (0.22 g,
0.59 mmol) with PPA (10 g); Yield: 57%; white solid; mp: 287-288 C; IR (KBr) ν
1
(cm-1): 1653.07 (C=O); H NMR (200 MHz, DMSO-d6): δ 3.60 (s, 6H, 2 × -OCH3),
3.80 (s, 3H, -OCH3), 5.99, 6.03 (s, each 1H, -O-CH2-O-), 6.26 (s, 1H, Ar-H), 6.32 (s,
13
2H, Ar-H), 6.81 (s, 1H, Ar-H), 8.26 (s, 1H, Ar-H), 11.62 (br. s, 1H, NH); C NMR
(50 MHz, DMSO-d6): δ 55.81, 56.17 (2C), 91.46 (2C), 95.73, 102.14, 103.52, 106.78,
114.72, 121.07, 136.01, 143.64, 146.02, 150.15, 158.19 (2C), 161.92, 162.10; MS (EI,
70 eV) m/z: 355.3 (M+); HRMS (EI) m/z: calculated for C19H17NO6: 355.1056; found:
355.1048.
5.2.3.11. 6,7-Methylenedioxy-4-(3,4,5-trimethoxyphenyl)quinolin-2(1H)-one
(12k)
Compound 12k (0.17 g, 0.48 mmol) was obtained by cyclization of 11k (0.25 g,
0.67 mmol) with PPA (10 g); Yield: 71%; white solid; mp: 275-276 C; IR (KBr) ν
(cm-1): 1647.28 (C=O); 1H NMR (200 MHz, DMSO-d6): δ 3.68 (s, 3H, -OCH3), 3.75
(s, 6H, 2 × -OCH3), 6.03 (s, 2H, -O-CH2-O-), 6.23 (s, 1H, Ar-H), 6.65 (s, 2H, Ar-H),
6.79 (s, 1H, Ar-H), 6.86 (s, 1H, Ar-H), 11.72 (br. s, 1H, NH); 13C NMR (50 MHz,
DMSO-d6): δ 56.48 (2C), 60.53, 96.00, 102.37, 103.97, 106.36 (2C), 113.07, 118.65,
133.12, 136.68, 138.03, 143.87, 150.52, 151.91, 153.39 (2C), 161.75; MS (EI, 70 eV)
m/z: 355.2 (M+); HRMS (EI) m/z: calculated for C19H17NO6: 355.1056; found:
355.1050.
5.2.3.12. 4-(2-Fluorophenyl)-6,7-methylenedioxyquinolin-2(1H)-one (12l)
Compound 12l (0.11 g, 0.39 mmol) was obtained by cyclization of 11l (0.21 g,
27

0.70 mmol) with PPA (10 g); Yield: 55%; white solid; mp: 251-252 C; IR (KBr) ν
1
(cm-1): 1653.07 (C=O); H NMR (200 MHz, DMSO-d6): δ 6.06 (s, 2H, -O-CH2-O-),
6.29 (s, 1H, Ar-H), 6.45 (d, J = 2.0 Hz, 1H, Ar-H), 6.91 (s, 1H, Ar-H), 7.33-7.47 (m,
3H, Ar-H), 7.51-7.62 (m, 1H, Ar-H), 11.87 (br. s, 1H, NH); 13C NMR (50 MHz,
2
DMSO-d6): δ 95.99, 102.47, 103.42, 112.96, 116.38 (d, JCF = 21.5 Hz, 1C), 120.11,
124.89 (d, 2JCF = 15.8 Hz, 1C), 125.52, 131.39, 131.67 (d, 3JCF = 8.0 Hz, 1C), 136.46,
144.04, 146.18, 150.73, 159.02 (d, 1JCF = 245.0 Hz, 1C), 161.47; MS (EI, 70 eV) m/z:
283.1 (M+); HRMS (EI) m/z: calculated for C16H10FNO3: 283.0645; found: 283.0641.
5.2.3.13. 4-(3-Fluorophenyl)-6,7-methylenedioxyquinolin-2(1H)-one (12m)
Compound 12m (0.13 g, 0.46 mmol) was obtained by cyclization of 11m (0.21 g,
0.70 mmol) with PPA (10 g); Yield: 65%; white solid; mp: 249-251 C; IR (KBr) ν
1
(cm-1): 1654.03 (C=O); H NMR (200 MHz, DMSO-d6): δ 6.07 (s, 2H, -O-CH2-O-),
6.25 (s, 1H, Ar-H), 6.67 (s, 1H, Ar-H), 6.90 (s, 1H, Ar-H), 7.24-7.37 (m, 3H, Ar-H),
13
7.51-7.62 (m, 1H, Ar-H), 11.81 (br. s, 1H, NH); C NMR (50 MHz, DMSO-d6): δ
96.08, 102.44, 103.64, 112.62, 115.97 (d, 2JCF = 23.0 Hz, 2C), 119.08, 125.22, 131.28
(d, 3JCF = 8.5 Hz, 1C), 136.83, 139.84 (d, 3JCF = 8.0 Hz, 1C), 143.94, 150.38, 150.64,
161.51, 162.54 (d, 1JCF = 243.5 Hz, 1C); MS (EI, 70 eV) m/z: 283.1 (M+); HRMS (EI)
m/z: calculated for C16H10FNO3: 283.0645; found: 283.0648.
5.2.3.14. 4-(4-Fluorophenyl)-6,7-methylenedioxyquinolin-2(1H)-one (12n)
Compound 12b (0.17 g, 0.60 mmol) was obtained by cyclization of 11b (0.21 g,
0.70 mmol) with PPA (10 g); Yield: 85%; white solid; mp: 251-252 C; IR (KBr) ν
1
(cm-1): 1668.50 (C=O); H NMR (200 MHz, DMSO-d6): δ 6.02 (s, 2H, -O-CH2-O-),
6.19 (s, 1H, Ar-H), 6.62 (s, 1H, Ar-H), 6.86 (s, 1H, Ar-H), 7.25-7.34 (m, 2H, Ar-H),
13
7.40-7.47 (m, 2H, Ar-H), 11.76 (br. s, 1H, NH); C NMR (50 MHz, DMSO-d6): δ
96.06, 102.41, 103.67, 112.90, 116.11 (d, 2JCF = 22.0 Hz, 2C), 119.02, 131.15 (d, 3JCF
28

1
= 8.5 Hz, 2C), 133.94, 136.79, 143.88, 150.56, 150.74, 161.58, 162.70 (d, JCF
=
244.5 Hz, 1C); MS (EI, 70 eV) m/z: 283.1 (M+); HRMS (EI) m/z: calculated for
C16H10FNO3: 283.0645; found: 283.0636.
5.3. Biological evaluation
5.3.1. Antiproliferative assay
Human tumor cell lines of the cancer screening panel were maintained in
RPMI-1640 medium supplemented with 10% fetal bovine serum (GIBCO/BRL),
penicillin (100 U/mL)/streptomycin (100 g/mL) (GIBCO/BRL) and 1% L-glutamine
(GIBCO/BRL) at 37 C in a humidified atmosphere containing 5% CO2. Human
hepatoma Hep 3B and normal skin Detroit 551 cells were maintained in DMEM
medium supplemented with 10% fetal bovine serum (GIBCO/BRL), penicillin (100
U/mL)/streptomycin (100 g/mL) (GIBCO/BRL) and 1% L-glutamine (GIBCO/BRL)
at 37 C in a humidified atmosphere containing 5% CO2. Logarithmically growing
cancer cells were used for all experiments. The human tumor cell lines were treated
with vehicle or test compounds for 48 h. Cell growth rate was determined by MTT
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliun bromide] reduction assay.37,38
After 48 h treatment, cell growth rate was measured by scanning with an ELISA
reader with a 570 nm filter and the IC50 values of test compounds were calculated.
5.3.2. Hoechst 33258 staining
HL-60 cells were plated at a density of 1×105 cells per well in 24-well plates and
then incubated with 0.25 μM, 0.5 μM, and 1.0 μM, of compound 12e for 24 h. H460
cells were plated at a density of 5×104 cells per well in 24-well plates and then
incubated with 1.0 μM, 2.5 μM, and 5.0 μM, of compound 12e for 24 h. Cells were
examined directly and photographed under a phase contrast microscope. Nuclei were
stained with Hoechst 33258 (bis-benzimide, Sigma) to detect chromatin condensation
29